Reports from Tempus Labs Inc. Provide New Insights into Cancer Research (Assessing the Utility of Molecular Diagnostic Classification for Cancers of Unknown Primary).
In: Cancer Weekly, 2023-10-17, S. 805-805
serialPeriodical
Zugriff:
Results from the molecular diagnostic classifier changed the consensus oncologist-reported treatment recommendations for 235 out of 289 patients (81.3%). Keywords: Chicago; State:Illinois; United States; North and Central America; Cancer Research; Business; Cancer; Diagnostics and Screening; Health and Medicine; Legal Issues; Oncology EN Chicago State:Illinois United States North and Central America Cancer Research Business Cancer Diagnostics and Screening Health and Medicine Legal Issues Oncology 805 805 1 10/16/23 20231017 NES 231017 2023 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Cancer Research have been published. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
| Titel: |
Reports from Tempus Labs Inc. Provide New Insights into Cancer Research (Assessing the Utility of Molecular Diagnostic Classification for Cancers of Unknown Primary).
|
|---|---|
| Zeitschrift: | Cancer Weekly, 2023-10-17, S. 805-805 |
| Veröffentlichung: | 2023 |
| Medientyp: | serialPeriodical |
| ISSN: | 1071-7218 (print) |
| Schlagwort: |
|
| Sonstiges: |
|